A recent study evaluates the cost-effectiveness of dabrafenib and trametinib for treating pediatric patients with BRAF V600E mutation low-grade glioma in England and Wales. This research could influence treatment decisions and healthcare resource allocation for this patient population.
evaluating the cost effectiveness of dabrafenib and trametinib for the treatment of paediatric patients with a braf v600e mutation low grade glioma in england and wales
Original title: “Evaluating the cost-effectiveness of dabrafenib and trametinib for the treatment of paediatric patients with a BRAF V600E mutation low-grade glioma in England and Wales.”